acyl-CoA synthetase medium chain family member 2BGenealiases: ACSM2 · HXMA · HYST1046
Q-omics provides the consensus-scored ACSM2B profile across patient tissues and cancer cell-line models. ACSM2B expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ACSM2B is differentially expressed in 13, with the highest sampling consensus in KICH. Additionally, ACSM2B protein abundance shows 8,561 significant protein co-abundance associations, with the highest sampling consensus in CCRCC. Together, these results highlight KIRC, KICH, and CCRCC as cancer lineages where ACSM2B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ACSM2B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ACSM2B survival associations across molecular data types. ACSM2B RNA expression shows survival associations in the most cancer types (19), followed by mutation status (9) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ACSM2B RNA expression–survival associations across cancer types. High ACSM2B expression shows unfavorable associations in CHOL, but favorable associations in KIRC, BRCA, LIHC, READ and UCEC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify KIRC as the clearest survival context for ACSM2B RNA expression.
This table summarizes ACSM2B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 3. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ACSM2B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ACSM2B shows lower tumor expression in KICH, THCA, LUAD, COAD, KIRP and BRCA. The KICH box plot shows higher ACSM2B RNA expression in normal versus tumor tissue (log2 FC = −4.847, t-test p < 0.001).
This table shows molecular features associated with ACSM2B in patient tissues and cancer cell lines. In patient samples, ACSM2B shows the broadest associations at the RNA and protein expression levels, with CCRCC recurring as the lineage with the largest associated feature set. In cancer cell lines, ACSM2B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in CNS and LUNG_NSCLC_LUAD.
